Hyderabad-based pharmaceuticals giant Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) for Ceftriaxone injection, in the strengths of 250 mg, 500 mg, 1g, 2g and 10g.

Ceftriaxone, generally used for severe infections, belongs to a group of antibiotics called the cephalosporins.

In recently announced results, Aurobindo Pharma has reported a 73% fall in quarterly net profit hit by foreign exchange-related charges.

The pharmaceutical major has registered 31% decline in its standalone net profit to Rs 39.87 crore for the quarter ended June 2008 compared to Rs 58.54 crore during the same quarter last year.

Its total income grew 27.64 per cent to Rs 684.7 crore, as against Rs 536.4 crore.